Skip to main content

Advertisement

SpringerLink
Log in

Current Status of Potential Therapies for IgE-Mediated Food Allergy

  • Food Allergy (T Green, Section Editor)
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The goal of this review is to provide the reader with an updated summary of published trial data regarding the use of oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT) for treatment of IgE-mediated food allergies.

Recent Findings

Data from phase 2 trials for treatment of peanut allergy with OIT and EPIT reveal an increase in the threshold of reactivity for peanut-allergic children. Compared to EPIT, OIT promotes a greater increase in the threshold of reactivity; however, adverse events are more common with OIT.

Summary

OIT, EPIT, and SLIT appear to modulate the immune response for some food-allergic individuals. Data regarding utility for treatment of food allergies regardless of modality is limited to few foods, as is investigation into treatment of food-allergic infants, young children, and adults. Future trials are likely to focus on young children, food allergies other than peanut, and treatment of multifood-allergic individuals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Gupta RS, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics. 2011;128(1):e9–17. https://doi.org/10.1542/peds.2011-0204.

    Article  PubMed  Google Scholar 

  2. Nwaru BI, Hickstein L, Panesar SS, Roberts G, Muraro A, Sheikh A, et al. Prevalence of common food allergies in Europe: a systematic review and meta-analysis. Allergy. 2014;69(8):992–1007. https://doi.org/10.1111/all.12423.

    Article  CAS  PubMed  Google Scholar 

  3. Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention and management. J Allergy Clin Immunol. 2017; https://doi.org/10.1016/j.jaci.2017.11.003.

  4. Flokstra-de Blok BM, Dubois AE, Vlieg-Boerstra BJ, Oude Elberink JN, Raat H, DunnGalvin A, et al. Health-related quality of life of food allergic patients: comparison with the general population and other diseases. Allergy. 2010;65(2):238–44. https://doi.org/10.1111/j.1398-9995.2009.02121.x.

    Article  CAS  PubMed  Google Scholar 

  5. Mansfield L. Successful oral desensitization for systemic peanut allergy. Ann Allergy Asthma Immunol. 2006;97(2):266–7. https://doi.org/10.1016/S1081-1206(10)60026-9.

    Article  PubMed  Google Scholar 

  6. Patriarca G, Nucera E, Pollastrini E, De Pasquale T, Lombardo C, Buonomo A, et al. Oral rush desensitization in peanut allergy: a case report. Dig Dis Sci. 2006;51(3):471–3. https://doi.org/10.1007/s10620-006-3157-4.

    Article  PubMed  Google Scholar 

  7. Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011;127(3):654–60. https://doi.org/10.1016/j.jaci.2010.12.1111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Vickery BP, Scurlock AM, Kulis M, Steele PH, Kamilaris J, Berglund JP, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol. 2014;133(2):468–75 e6. https://doi.org/10.1016/j.jaci.2013.11.007.

    Article  CAS  PubMed  Google Scholar 

  9. Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135(5):1275–82 e1–6. https://doi.org/10.1016/j.jaci.2014.11.005.

  10. Syed A, Garcia MA, Lyu SC, Bucayu R, Kohli A, Ishida S, et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol. 2014;133(2):500–10. https://doi.org/10.1016/j.jaci.2013.12.1037.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372(9):803–13. https://doi.org/10.1056/NEJMoa1414850.

    Article  PubMed  PubMed Central  Google Scholar 

  12. • Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol. 2017;139(1):173–81 e8. https://doi.org/10.1016/j.jaci.2016.05.027. First report suggesting peanut OIT for peanut-allergic children in early childhood (9–36 mos) is safe and may lead to a higher likelihood of inducing SU.

    Article  CAS  PubMed  Google Scholar 

  13. •• Bird JA, Spergel JM, Jones SM, Rachid R, Assa’ad AH, Wang J et al. Efficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract 2017. https://doi.org/10.1016/j.jaip.2017.09.016 . Multi-center phase 2 trial using a standardized product for OIT showing safe and effective desensitization for peanut-allergic children, adolescents and young adults.

  14. Patriarca G, Nucera E, Roncallo C, Pollastrini E, Bartolozzi F, De Pasquale T, et al. Oral desensitizing treatment in food allergy: clinical and immunological results. Aliment Pharmacol Ther. 2003;17(3):459–65. https://doi.org/10.1046/j.1365-2036.2003.01468.x.

    Article  CAS  PubMed  Google Scholar 

  15. Patriarca G, Schiavino D, Nucera E, Schinco G, Milani A, Gasbarrini GB. Food allergy in children: results of a standardized protocol for oral desensitization. Hepato-Gastroenterology. 1998;45(19):52–8.

    CAS  PubMed  Google Scholar 

  16. Meglio P, Bartone E, Plantamura M, Arabito E, Giampietro PG. A protocol for oral desensitization in children with IgE-mediated cow’s milk allergy. Allergy. 2004;59(9):980–7. https://doi.org/10.1111/j.1398-9995.2004.00542.x.

    Article  CAS  PubMed  Google Scholar 

  17. Zapatero L, Alonso E, Fuentes V, Martinez MI. Oral desensitization in children with cow’s milk allergy. J Investig Allergol Clin Immunol. 2008;18(5):389–96.

    CAS  PubMed  Google Scholar 

  18. Alvaro M, Giner MT, Vazquez M, Lozano J, Dominguez O, Piquer M, et al. Specific oral desensitization in children with IgE-mediated cow’s milk allergy. Evolution in one year. Eur J Pediatr. 2012;171(9):1389–95. https://doi.org/10.1007/s00431-012-1739-z.

    Article  CAS  PubMed  Google Scholar 

  19. Sanchez-Garcia S, Rodriguez del Rio P, Escudero C, Garcia-Fernandez C, Ramirez A, Ibanez MD. Efficacy of oral immunotherapy protocol for specific oral tolerance induction in children with cow’s milk allergy. Isr Med Assoc J. 2012;14(1):43–7.

    PubMed  Google Scholar 

  20. Staden U, Rolinck-Werninghaus C, Brewe F, Wahn U, Niggemann B, Beyer K. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction. Allergy. 2007;62(11):1261–9. https://doi.org/10.1111/j.1398-9995.2007.01501.x.

    Article  CAS  PubMed  Google Scholar 

  21. Skripak JM, Nash SD, Rowley H, Brereton NH, Oh S, Hamilton RG, et al. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow’s milk allergy. J Allergy Clin Immunol. 2008;122(6):1154–60. https://doi.org/10.1016/j.jaci.2008.09.030.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Narisety SD, Skripak JM, Steele P, Hamilton RG, Matsui EC, Burks AW, et al. Open-label maintenance after milk oral immunotherapy for IgE-mediated cow’s milk allergy. J Allergy Clin Immunol. 2009;124(3):610–2. https://doi.org/10.1016/j.jaci.2009.06.025.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012;129(2):448–55, 55 e1–5. https://doi.org/10.1016/j.jaci.2011.10.023.

  24. Paassilta M, Salmivesi S, Maki T, Helminen M, Korppi M. Children who were treated with oral immunotherapy for cows' milk allergy showed long-term desensitisation seven years later. Acta Paediatr. 2016;105(2):215–9. https://doi.org/10.1111/apa.13251.

    Article  CAS  PubMed  Google Scholar 

  25. Keet CA, Seopaul S, Knorr S, Narisety S, Skripak J, Wood RA. Long-term follow-up of oral immunotherapy for cow’s milk allergy. J Allergy Clin Immunol. 2013;132(3):737–9 e6. https://doi.org/10.1016/j.jaci.2013.05.006.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Pajno GB, Caminiti L, Ruggeri P, De Luca R, Vita D, La Rosa M, et al. Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Ann Allergy Asthma Immunol. 2010;105(5):376–81. https://doi.org/10.1016/j.anai.2010.03.015.

    Article  CAS  PubMed  Google Scholar 

  27. Buchanan AD, Green TD, Jones SM, Scurlock AM, Christie L, Althage KA, et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol. 2007;119(1):199–205. https://doi.org/10.1016/j.jaci.2006.09.016.

    Article  CAS  PubMed  Google Scholar 

  28. Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012;367(3):233–43. https://doi.org/10.1056/NEJMoa1200435.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Jones SM, Burks AW, Keet C, Vickery BP, Scurlock AM, Wood RA et al. Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy. J Allergy Clin Immunol. 2016;137(4):1117–27 e1–10. https://doi.org/10.1016/j.jaci.2015.12.1316.

  30. Escudero C, Rodriguez Del Rio P, Sanchez-Garcia S, Perez-Rangel I, Perez-Farinos N, Garcia-Fernandez C, et al. Early sustained unresponsiveness after short-course egg oral immunotherapy: a randomized controlled study in egg-allergic children. Clin Exp Allergy. 2015;45(12):1833–43. https://doi.org/10.1111/cea.12604.

    Article  CAS  PubMed  Google Scholar 

  31. Caminiti L, Pajno GB, Crisafulli G, Chiera F, Collura M, Panasci G, et al. Oral immunotherapy for egg allergy: a double-blind placebo-controlled study, with postdesensitization follow-up. J Allergy Clin Immunol Pract. 2015;3(4):532–9. https://doi.org/10.1016/j.jaip.2015.01.017.

    Article  PubMed  Google Scholar 

  32. Lemon-Mule H, Sampson HA, Sicherer SH, Shreffler WG, Noone S, Nowak-Wegrzyn A. Immunologic changes in children with egg allergy ingesting extensively heated egg. J Allergy Clin Immunol. 2008;122(5):977–83 e1. https://doi.org/10.1016/j.jaci.2008.09.007.

    Article  CAS  PubMed  Google Scholar 

  33. Nowak-Wegrzyn A, Bloom KA, Sicherer SH, Shreffler WG, Noone S, Wanich N et al. Tolerance to extensively heated milk in children with cow’s milk allergy. J Allergy Clin Immunol. 2008;122(2):342–7, 7 e1–2. https://doi.org/10.1016/j.jaci.2008.05.043.

  34. Wood RA, Sicherer SH, Vickery BP, Jones SM, Liu AH, Fleischer DM, et al. The natural history of milk allergy in an observational cohort. J Allergy Clin Immunol. 2013;131(3):805–12. https://doi.org/10.1016/j.jaci.2012.10.060.

    Article  CAS  PubMed  Google Scholar 

  35. Sicherer SH, Wood RA, Vickery BP, Jones SM, Liu AH, Fleischer DM, et al. The natural history of egg allergy in an observational cohort. J Allergy Clin Immunol. 2014;133(2):492–9. https://doi.org/10.1016/j.jaci.2013.12.1041.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Goldberg MR, Nachshon L, Appel MY, Elizur A, Levy MB, Eisenberg E, et al. Efficacy of baked milk oral immunotherapy in baked milk-reactive allergic patients. J Allergy Clin Immunol. 2015;136(6):1601–6. https://doi.org/10.1016/j.jaci.2015.05.040.

    Article  CAS  PubMed  Google Scholar 

  37. Bravin K, Luyt D. Home-based oral immunotherapy with a baked egg protocol. J Investig Allergol Clin Immunol. 2016;26(1):61–3.

    CAS  PubMed  Google Scholar 

  38. Giavi S, Vissers YM, Muraro A, Lauener R, Konstantinopoulos AP, Mercenier A, et al. Oral immunotherapy with low allergenic hydrolysed egg in egg allergic children. Allergy. 2016;71(11):1575–84. https://doi.org/10.1111/all.12905.

    Article  CAS  PubMed  Google Scholar 

  39. Rodriguez del Rio P, Diaz-Perales A, Sanchez-Garcia S, Escudero C, do Santos P, Catarino M, et al. Oral immunotherapy in children with IgE-mediated wheat allergy: outcome and molecular changes. J Investig Allergol Clin Immunol. 2014;24(4):240–8.

    CAS  PubMed  Google Scholar 

  40. Sato S, Utsunomiya T, Imai T, Yanagida N, Asaumi T, Ogura K, et al. Wheat oral immunotherapy for wheat-induced anaphylaxis. J Allergy Clin Immunol. 2015;136(4):1131–3 e7. https://doi.org/10.1016/j.jaci.2015.07.019.

    Article  PubMed  Google Scholar 

  41. Nowak-Wegrzyn A, Wood RA, Nadeau KC, Pongracic JA, Henning A, Beyer K, et al. Randomized placebo-controlled multicenter clinical trial of wheat oral immunotherapy. J Allergy Clin Immunol. 2017;139((2):AB378. https://doi.org/10.1016/j.jaci.2016.12.904.

    Article  Google Scholar 

  42. Gupta N, Aron AR. Urges for food and money spill over into motor system excitability before action is taken. Eur J Neurosci. 2011;33(1):183–8. https://doi.org/10.1111/j.1460-9568.2010.07510.x.

    Article  PubMed  Google Scholar 

  43. Bird JA, Kulis M, Burk CM, Vickery BP, Jones SM, Burks W. Tree nut- and sesame-specific IgE do not decrease from baseline with peanut oral immunotherapy (OIT). Ann Allergy Asthma Immunol. 2012;109(6):470–1. https://doi.org/10.1016/j.anai.2012.09.004.

    Article  CAS  PubMed  Google Scholar 

  44. Begin P, Winterroth LC, Dominguez T, Wilson SP, Bacal L, Mehrotra A, et al. Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. Allergy Asthma Clin Immunol. 2014;10(1):1. https://doi.org/10.1186/1710-1492-10-1.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Begin P, Dominguez T, Wilson SP, Bacal L, Mehrotra A, Kausch B, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab. Allergy Asthma Clin Immunol. 2014;10(1):7. https://doi.org/10.1186/1710-1492-10-7.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Hofmann AM, Scurlock AM, Jones SM, Palmer KP, Lokhnygina Y, Steele PH, et al. Safety of a peanut oral immunotherapy protocol in children with peanut allergy. J Allergy Clin Immunol. 2009;124(2):286–91, 91 e1–6. https://doi.org/10.1016/j.jaci.2009.03.045.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Wasserman RL, Factor JM, Baker JW, Mansfield LE, Katz Y, Hague AR, et al. Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions. J Allergy Clin Immunol Pract. 2014;2(1):91–6. https://doi.org/10.1016/j.jaip.2013.10.001.

    Article  PubMed  Google Scholar 

  48. Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M, et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol. 2009;124(2):292–300, e1-97. https://doi.org/10.1016/j.jaci.2009.05.022.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. •• Virkud YV, Burks AW, Steele PH, Edwards LJ, Berglund JP, Jones SM et al. Novel baseline predictors of adverse events during oral immunotherapy in children with peanut allergy. J Allergy Clin Immunol. 2017;139(3):882-8 e5. https://doi.org/10.1016/j.jaci.2016.07.030. Comprehensive retrospective analysis of peanut-allergic children receiving OIT that shows an increased reaction rate while receiving OIT compared to avoidance.

  50. Varshney P, Steele PH, Vickery BP, Bird JA, Thyagarajan A, Scurlock AM, et al. Adverse reactions during peanut oral immunotherapy home dosing. J Allergy Clin Immunol. 2009;124(6):1351–2. https://doi.org/10.1016/j.jaci.2009.09.042.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Lucendo AJ, Arias A, Tenias JM. Relation between eosinophilic esophagitis and oral immunotherapy for food allergy: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2014;113(6):624–9. https://doi.org/10.1016/j.anai.2014.08.004.

    Article  PubMed  Google Scholar 

  52. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med. 2006;355(14):1445–55. https://doi.org/10.1056/NEJMoa052916.

    Article  CAS  PubMed  Google Scholar 

  53. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy. 2001;56(6):498–505. https://doi.org/10.1034/j.1398-9995.2001.056006498.x.

    Article  CAS  PubMed  Google Scholar 

  54. Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol. 2004;113(6):1144–51. https://doi.org/10.1016/j.jaci.2004.03.003.

    Article  CAS  PubMed  Google Scholar 

  55. Lombardi V, Van Overtvelt L, Horiot S, Moussu H, Chabre H, Louise A, et al. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin Exp Allergy. 2008;38(11):1819–29. https://doi.org/10.1111/j.1365-2222.2008.03056.x.

    CAS  PubMed  Google Scholar 

  56. Mascarell L, Van Overtvelt L, Lombardi V, Razafindratsita A, Moussu H, Horiot S, et al. A synthetic triacylated pseudo-dipeptide molecule promotes Th1/TReg immune responses and enhances tolerance induction via the sublingual route. Vaccine. 2007;26(1):108–18. https://doi.org/10.1016/j.vaccine.2007.10.050.

    Article  CAS  PubMed  Google Scholar 

  57. Pessi T, Sutas Y, Hurme M, Isolauri E. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy. 2000;30(12):1804–8. https://doi.org/10.1046/j.1365-2222.2000.00948.x.

    Article  CAS  PubMed  Google Scholar 

  58. Miettinen M, Matikainen S, Vuopio-Varkila J, Pirhonen J, Varkila K, Kurimoto M, et al. Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells. Infect Immun. 1998;66(12):6058–62.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Pohjavuori E, Viljanen M, Korpela R, Kuitunen M, Tiittanen M, Vaarala O, et al. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow’s milk allergy. J Allergy Clin Immunol. 2004;114(1):131–6. https://doi.org/10.1016/j.jaci.2004.03.036.

    Article  CAS  PubMed  Google Scholar 

  60. Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol. 2002;109(1):119–21. https://doi.org/10.1067/mai.2002.120273.

    Article  PubMed  Google Scholar 

  61. Rautava S, Arvilommi H, Isolauri E. Specific probiotics in enhancing maturation of IgA responses in formula-fed infants. Pediatr Res. 2006;60(2):221–4. https://doi.org/10.1203/01.pdr.0000228317.72933.db.

    Article  PubMed  Google Scholar 

  62. Tang ML, Ponsonby AL, Orsini F, Tey D, Robinson M, Su EL, et al. Administration of a probiotic with peanut oral immunotherapy: a randomized trial. J Allergy Clin Immunol. 2015;135(3):737–44 e8. https://doi.org/10.1016/j.jaci.2014.11.034.

    Article  CAS  PubMed  Google Scholar 

  63. Hsiao K-C, Ponsonby A-L, Axelrad C, Pitkin S, Tang MLK, Burks W, et al. Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. The Lancet Child Adolescent Health. 2017;1(2):97–105. https://doi.org/10.1016/s2352-4642(17)30041-x.

    Article  Google Scholar 

  64. Dunn Galvin A, McMahon S, Ponsonby AL, Hsiao KC, Tang MLK, team Ps. The longitudinal impact of probiotic and peanut oral immunotherapy (PPOIT) on health related quality of life (HRQL). Allergy 2017. https://doi.org/10.1111/all.13330.

  65. Shaker MS. An economic analysis of a peanut oral immunotherapy study in children. J Allergy Clin Immunol Pract. 2017;5(6):1707–16. https://doi.org/10.1016/j.jaip.2017.04.016.

    Article  PubMed  Google Scholar 

  66. Savage JH, Courneya JP, Sterba PM, Macglashan DW, Saini SS, Wood RA. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol. 2012;130(5):1123–9 e2. https://doi.org/10.1016/j.jaci.2012.05.039.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM, et al. A phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127(5):1309–10 e1. https://doi.org/10.1016/j.jaci.2011.01.051.

    Article  CAS  PubMed  Google Scholar 

  68. Leung DY, Sampson HA, Yunginger JW, Burks AW, Jr., Schneider LC, Wortel CH et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003;348(11):986–993. https://doi.org/10.1056/NEJMoa022613.

  69. Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol. 2011;127(6):1622–4. https://doi.org/10.1016/j.jaci.2011.04.009.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013;132(6):1368–74. https://doi.org/10.1016/j.jaci.2013.09.046.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137(4):1103–10 e1–11. https://doi.org/10.1016/j.jaci.2015.10.005.

  72. MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2016; https://doi.org/10.1016/j.jaci.2016.08.010.

  73. Lafuente I, Mazon A, Nieto M, Uixera S, Pina R, Nieto A. Possible recurrence of symptoms after discontinuation of omalizumab in anti-IgE-assisted desensitization to egg. Pediatr Allergy Immunol. 2014;25(7):717–9. https://doi.org/10.1111/pai.12259.

    Article  PubMed  Google Scholar 

  74. Srivastava KD, Siefert A, Fahmy TM, Caplan MJ, Li XM, Sampson HA. Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy. J Allergy Clin Immunol. 2016;138(2):536–43 e4. https://doi.org/10.1016/j.jaci.2016.01.047.

    Article  CAS  PubMed  Google Scholar 

  75. Bannon GA, Cockrell G, Connaughton C, West CM, Helm R, Stanley JS, et al. Engineering, characterization and in vitro efficacy of the major peanut allergens for use in immunotherapy. Int Arch Allergy Immunol. 2001;124(1–3):70–2. 53672. https://doi.org/10.1159/000053672.

    Article  CAS  PubMed  Google Scholar 

  76. Srivastava KDLX, King N, Stanley S, Bannon GA, Burks W, Sampson HA. Immunotherapy with modified peanut allergens in a murine model of peanut allergy. J Allergy Clin Immunol. 2002;109(1):S287. https://doi.org/10.1016/S0091-6749(02)82012-7.

    Article  Google Scholar 

  77. Wood RA, Sicherer SH, Burks AW, Grishin A, Henning AK, Lindblad R, et al. A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins Ara h 1, Ara h 2, and Ara h 3 (EMP-123) for the treatment of peanut allergy. Allergy. 2013;68(6):803–8. https://doi.org/10.1111/all.12158.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Swoboda I, Bugajska-Schretter A, Linhart B, Verdino P, Keller W, Schulmeister U, et al. A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy. J Immunol. 2007;178(10):6290–6. https://doi.org/10.4049/jimmunol.178.10.6290.

    Article  CAS  PubMed  Google Scholar 

  79. Dioszeghy V, Mondoulet L, Dhelft V, Ligouis M, Puteaux E, Dupont C, et al. The regulatory T cells induction by epicutaneous immunotherapy is sustained and mediates long-term protection from eosinophilic disorders in peanut-sensitized mice. Clin Exp Allergy. 2014;44(6):867–81. https://doi.org/10.1111/cea.12312.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Tordesillas L, Mondoulet L, Blazquez AB, Benhamou PH, Sampson HA, Berin MC. Epicutaneous immunotherapy induces gastrointestinal LAP+ regulatory T cells and prevents food-induced anaphylaxis. J Allergy Clin Immunol. 2017;139(1):189–201.e4. https://doi.org/10.1016/j.jaci.2016.03.057.

    Article  CAS  PubMed  Google Scholar 

  81. Dioszeghy V, Mondoulet L, Dhelft V, Ligouis M, Puteaux E, Benhamou PH, et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol. 2011;186(10):5629–37. https://doi.org/10.4049/jimmunol.1003134.

    Article  CAS  PubMed  Google Scholar 

  82. Mondoulet L, Dioszeghy V, Ligouis M, Dhelft V, Dupont C, Benhamou PH. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy. 2010;40(4):659–67. https://doi.org/10.1111/j.1365-2222.2009.03430.x.

    Article  CAS  PubMed  Google Scholar 

  83. Dupont C, Kalach N, Soulaines P, Legoue-Morillon S, Piloquet H, Benhamou PH. Cow’s milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol. 2010;125(5):1165–7. https://doi.org/10.1016/j.jaci.2010.02.029.

    Article  CAS  PubMed  Google Scholar 

  84. Jones SM, Agbotounou WK, Fleischer DM, Burks AW, Pesek RD, Harris MW, et al. Safety of epicutaneous immunotherapy for the treatment of peanut allergy: a phase 1 study using the Viaskin patch. J Allergy Clin Immunol. 2016;137(4):1258–61 e10. https://doi.org/10.1016/j.jaci.2016.01.008.

    Article  PubMed  Google Scholar 

  85. Jones SM, Sicherer SH, Burks AW, Leung DY, Lindblad RW, Dawson P, et al. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. J Allergy Clin Immunol. 2017;139(4):1242–52 e9. https://doi.org/10.1016/j.jaci.2016.08.017.

    Article  CAS  PubMed  Google Scholar 

  86. •• Sampson HA, Shreffler WG, Yang WH, Sussman GL, Brown-Whitehorn TF, Nadeau KC, et al. Effect of varying doses of epicutaneous immunotherapy vs placebo on reaction to peanut protein exposure among patients with peanut sensitivity: a randomized clinical trial. JAMA. 2017;318(18):1798–809. https://doi.org/10.1001/jama.2017.16591. Phase 2 clinical trial reporting the safety of EPIT for treatment of peanut allergy and suggesting an increased reactivity threshold after 1 year of treatment for children 4 to 11 years old.

    Article  PubMed  Google Scholar 

  87. Jay DC, Nadeau KC. Immune mechanisms of sublingual immunotherapy. Curr Allergy Asthma Rep. 2014;14(11):473. https://doi.org/10.1007/s11882-014-0473-1.

    Article  PubMed  Google Scholar 

  88. Enrique E, Pineda F, Malek T, Bartra J, Basagana M, Tella R, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol. 2005;116(5):1073–9. https://doi.org/10.1016/j.jaci.2005.08.027.

    Article  CAS  PubMed  Google Scholar 

  89. Enrique E, Malek T, Pineda F, Palacios R, Bartra J, Tella R, et al. Sublingual immunotherapy for hazelnut food allergy: a follow-up study. Ann Allergy Asthma Immunol. 2008;100(3):283–4. https://doi.org/10.1016/s1081-1206(10)60456-5.

    Article  PubMed  Google Scholar 

  90. de Boissieu D, Dupont C. Sublingual immunotherapy for cow's milk protein allergy: a preliminary report. Allergy. 2006;61(10):1238–9. https://doi.org/10.1111/j.1398-9995.2006.01196.x.

    Article  PubMed  Google Scholar 

  91. Fernandez-Rivas M, Garrido Fernandez S, Nadal JA, Diaz de Durana MD, Garcia BE, Gonzalez-Mancebo E, et al. Randomized double-blind, placebo-controlled trial of sublingual immunotherapy with a Pru p 3 quantified peach extract. Allergy. 2009;64(6):876–83. https://doi.org/10.1111/j.1398-9995.2008.01921.x.

    Article  CAS  PubMed  Google Scholar 

  92. Kim EH, Bird JA, Kulis M, Laubach S, Pons L, Shreffler W et al. Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol. 2011;127(3):640–6.e1. https://doi.org/10.1016/j.jaci.2010.12.1083.

  93. Fleischer DM, Burks AW, Vickery BP, Scurlock AM, Wood RA, Jones SM et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol. 2013;131(1):119–27.e1–7. https://doi.org/10.1016/j.jaci.2012.11.011.

  94. Burks AW, Wood RA, Jones SM, Sicherer SH, Fleischer DM, Scurlock AM et al. Sublingual immunotherapy for peanut allergy: long-term follow-up of a randomized multicenter trial. J Allergy Clin Immunol. 2015;135(5):1240–8.e1–3. https://doi.org/10.1016/j.jaci.2014.12.1917.

  95. Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG et al. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015;135(5):1275–82.e1–6. https://doi.org/10.1016/j.jaci.2014.11.005.

  96. Keet CA, Frischmeyer-Guerrerio PA, Thyagarajan A, Schroeder JT, Hamilton RG, Boden S et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J Allergy Clin Immunol. 2012;129(2):448–55, 55.e1–5. https://doi.org/10.1016/j.jaci.2011.10.023.

Download references

Author information

Authors and Affiliations

  1. Division of Allergy and Immunology, Departments of Pediatrics and Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390-9063, USA

    Christopher P. Parrish, Daniel Har & J. Andrew Bird

Authors
  1. Christopher P. Parrish
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Har
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Andrew Bird
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Andrew Bird.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Food Allergy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Parrish, C.P., Har, D. & Andrew Bird, J. Current Status of Potential Therapies for IgE-Mediated Food Allergy. Curr Allergy Asthma Rep 18, 18 (2018). https://doi.org/10.1007/s11882-018-0772-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11882-018-0772-z

Keywords

Search

Navigation